Whalesbook
Revenue Grows, But Profits Suffer
Indegene's revenue for the fourth quarter of fiscal year 2026 reached INR 10 billion, a 6.5% sequential increase, aligning with expectations. However, this revenue growth was overshadowed by a significant drop in profit. The company's EBITDA margin contracted by 60 basis points sequentially to 16.3%, falling short of analyst estimates. More alarmingly, year-on-year results for Q4 FY26 reveal a steeper margin contraction of 550 basis points to 17.4%, with net profit after tax (PAT) plummeting 32.2% to INR 0.8 billion. This decline was worsened by one-time costs, such as a INR 20.3 crore provision for litigation, which hid the core operational profit.
Working Capital Worries Signal Strain
Looking beyond the headline numbers, other operational figures suggest potential challenges. Indegene has experienced a concerning increase in working capital days, stretching from 61.8 days to 120 days. This means cash is tied up longer, potentially pressuring cash flow and efficiency, despite the revenue growth.
Valuation vs. Peers and Sector Growth
The company currently trades with a trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio in the range of 26x to 30x. This valuation is modest compared to the broader Indian Healthcare IT industry P/E of approximately 62.8x, and lower than some direct hospital sector peers like Max Healthcare (P/E 66.3x) or Fortis Healthcare (P/E 69.1x). However, this lower multiple may reflect market caution about Indegene's profit issues. The Indian Healthcare IT market itself is poised for strong growth, projected to expand at a compound annual growth rate (CAGR) of around 20% through 2033, driven by digital health adoption and government initiatives.
Stock Falls Despite Analyst Optimism
Despite the strong sector outlook, Indegene's stock has performed poorly, falling about 9% over the past year. This is despite generally positive analyst ratings, with most recommending 'Buy' or 'Outperform' and an average 12-month price target near INR 569. However, recent analyst price targets have edged down from over INR 600 earlier in 2026 to about INR 571 by April 2026, indicating some adjustments due to the company's recent performance.
Key Risks and Investor Cautions
Although Indegene is in a high-growth sector and has a strong balance sheet with little debt, several risks need attention. Repeated one-off costs, like the litigation provision, make earnings less clear and could hide ongoing margin problems. The sharp rise in working capital days points to potential operational issues that might affect future cash generation. Indegene's ability to meet its future revenue and earnings targets depends on effectively managing costs and dealing with margin pressures. Recent results show this is a challenge. While Indegene is a major player, its valuation multiples suggest the market is already accounting for these operational concerns compared to some rivals.
Analyst Outlook and What to Watch
Motilal Oswal forecasts Indegene will grow revenue by 19% and EBIT by 21% annually between FY25-28. They rate the stock 'Neutral' with a price target of INR 552. This target is based on a 20x multiple of FY28E EPS. The average analyst price target of INR 569 suggests some upside, but this optimism seems at odds with recent operational and profitability trends. Investors should closely monitor working capital management and margin trends in upcoming quarters to assess the sustainability of Indegene's growth story.